Evidence map›Paper›PMID 42064237›Full record

ArticleJournal of children's orthopaedics2026

What's new in pediatric bone sarcomas and benign bone tumors.

Nicolas von der Weid, Daniel Baumhoer, Andreas H Krieg

Abstract read
In one paragraph

Article in Journal of children's orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nicolas von der WeidPediatric Hematology-Oncology Department, University Children's Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-9555-3817
Daniel BaumhoerBone Tumor Reference Center, University Hospital Basel, Basel, Switzerland.
Andreas H KriegBone and Soft Tissue Tumor Center of the University of Basel (KWUB), Basel, Switzerland.ORCID https://orcid.org/0000-0001-6008-5657

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Significant progress has been made in the diagnosis and treatment of pediatric bone tumors in recent years. For malignant bone tumors, a better understanding of the molecular pathogenesis has been achieved, providing new directions for targeted approaches and immunotherapy. Advances in imaging techniques, such as whole-body magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography/computed tomography, have improved the accuracy of staging, treatment response evaluation, and recurrence monitoring. In surgical treatment, 3D printing technology, computer navigation, and minimally invasive techniques have shifted the paradigm from resection to functional reconstruction. Technologies, including modular and expandable implants, along with bio-integrated prostheses, support long-term functional recovery in pediatric patients. For benign bone tumors, the use of targeted drugs like denosumab and the refinement of minimally invasive techniques such as cryotherapy and radiofrequency ablation have achieved a better balance between disease control and functional preservation. The ongoing development of multidisciplinary collaboration further optimizes personalized treatment strategies. Looking ahead, continuous progress in precision medicine will steer the diagnosis and treatment of pediatric bone tumors toward minimally invasive, individualized, and innovative approaches.

Indexed as

immunotherapymolecular diagnosisPediatric bone tumorsprecision medicinetargeted therapy

Identifiers

PMID42064237
PMCPMC13124915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.